Effects of EEG- Microstate Neurofeedback on Attention and Impulsivity in Adult Attention-deficit/… (NCT05582928) | Clinical Trial Compass
UnknownNot Applicable
Effects of EEG- Microstate Neurofeedback on Attention and Impulsivity in Adult Attention-deficit/Hyperactivity Disorder (ADHD) and Neurotypical Controls
Switzerland60 participantsStarted 2022-09-19
Plain-language summary
EEG neurofeedback (NFB) may represent a new therapeutic opportunity for ADHD, a neuropsychiatric disorder characterized by attentional deficits and high impulsivity. Recent research of the Geneva group has demonstrated the ability of ADHD patients to control specific features of their EEG (notably alpha desynchronization) and that this control was associated with reduced impulsivity. In addition, alterations in EEG brain microstates (i.e., recurrent stable periods of short duration) have been described in adult ADHD patients, potentially representing a biomarker of the disorder. The present study aims to use neurofeedback to manipulate EEG microstates in ADHD patients and healthy controls, in order to observe the effects on neurophysiological, clinical and behavioural parameters.
Who can participate
Age range
18 Years – 50 Years
Sex
ALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
ADHD POPULATION GROUP
A subject will be eligible if all the following criteria apply:
* Age: between 18-50 years
* Gender: male and female
* Health: general good health and normal or corrected-to-normal visual acuity
* Patients clinically able to stop the following psychotropic medications for 48h: psychostimulants, benzodiazepines
* Having provided written informed written consent
A subject will not be eligible if any of the following criteria apply:
* Past or current history of a clinically significant central nervous system disorder, including structural brain abnormalities; cerebrovascular disease; history of other neurological disease, epilepsy, stroke or head trauma (defined as loss of consciousness \> 5 min or requiring hospitalization)
* Impaired vision (normal or corrected acuity below 20/40)
* Medical illness (e.g., cardiovascular disease, renal failure, hepatic dysfunction)
* Comorbidities with current psychiatric disorders (bipolar disorder, borderline personality disorder, major depressive disorder, anxiety disorder) including substance use disorder as defined by the DIGS.
HEALTHY POPULATION GROUP
A subject will be eligible if all of the following criteria apply:
* Age: between 18-50 years
* Gender: male and female
* Health: general good health and normal or corrected-to-normal visual acuity
* Having provided written informed written consent
A subject will not be eligible if any of the following criteria apply:
* Past or current history of ADHD
* Past or…
Questions worth asking your doctor
Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.
1Based on my diagnosis and history, is this trial worth exploring for me — or is there a standard treatment we should try first?
2What does this trial's phase tell us about how much is already known about its safety and benefit?
3What would taking part actually involve for me — visits, tests, time, and travel?
4What are the known and possible risks or side effects I should weigh, and how would they be monitored?
5If this trial isn't the right fit, what other options or trials would you suggest I look into?
Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.
Questions for the trial coordinator
The trial coordinator is the person who runs the study day to day. These cover the practical side — logistics, costs, and what taking part would actually mean for your life. The study team confirms whether you meet the criteria; these are questions to ask, not a sign you qualify.
1What does taking part actually involve week to week — how many visits, where, and how long does each one take?
2What costs are covered by the study, and what might I have to pay for myself, including travel, parking, or time off work?
3What happens during screening, and what happens if the study team confirms I don't meet the criteria after those tests?
4Who pays for the scans, blood work, and other tests the trial requires — the study, my insurance, or me?
5How will being in the trial affect my regular care, and will my own doctor stay informed and involved?
6Can I leave the trial at any point if I change my mind, and what would happen to my care if I do?
A starting point for the conversation — always confirm anything about your own eligibility, costs, and care with the study team and your doctor.
What they're measuring
1
Change in microstate coverage during training
Timeframe: Change within session at week 1 (session 2) and week 2 (session 2)
2
Change in microstate coverage during rest
Timeframe: Change within session week 1 (session 2) and week 2 (session 2)